Abstract
The biology of human multiple myeloma (MM) was poorly understood until recently. Only when IL-6 had been identified as an important growth factor for MM cells has it been possible to establish cell lines and to maintain fresh MM biopsy cells in vitro for weeks-months (Kawano et al 1988, Klein et al 1990, Nilsson et al 1990). This has allowed controlled in vitro studies of various aspects of the genotype and phenotype of MM cells during the 1990s. Some features are characteristic for MM cells. They include a restriction of the growth of MM cells almost exclusively to the bone marrow, chromosomal heterogeneity within and between individual MM clones, genetic instability, the presence at a high frequency of a translocation to the immunoglobulin (Ig) heavy chain or Ig light chain locus, a high and deregulated expression of c-Myc, a high expression of Bcl-2 and often a dependence of IL-6 and/or IGF-I as growth and survival factors. A common characteristic of MM cells both in vitro and in vivo is also that they proliferate slowly. At the population level the doubling time is often several days as a result of a long generation time (usually exceeding 36 hrs) and a high apoptotic rate. The first MM cell line established in our laboratory was in 1970 (Nilsson et al 1970). During the following decades additional MM lines were established (Nilsson, 1992) and a selected panel of lines, consisting also of MM cell lines established elsewhere, have been instrumental in studies on the control of growth and apoptosis during the last few years.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Brenning G, Ahre A, Nilsson K (1985) Correlation between in vitroand in vivosensitivity to human leucocyte interferon in patients with multiple myeloma. Scand J Haematol 35: 543 – 549
Corradini P, Inghirami G, Astolfi M, Ladetto M, Voena C, Ballerini P, Gu W, Nilsson K, Knowles DM, Boccadoro M, et al (1994) Inactivation of tumor suppressor genes, p53 and Rbl, in plasma cell dyscrasias. Leukemia 5: 758 – 767
Einhorn S, Strander H (1984) Studies with interferon-alpha in human tumors. Med Oncol Tumor Pharmacother 1:97-99 Evan G, Littlewood T (1998) A matter of life and cell death. Science 281: 1317 – 22
Evan G, Littlewood T (1998) A matter of life and cell death. Science 281:1317–22
Georgii-Hemming P, Strömberg T, Janson ET, Stridsberg M, Jernberg Wiklund H, Nilsson K (1999) The somatostatin analogue octreaotide inhibits growth of IL-6 dependent and IL-6 independent human multiple myeloma cell lines. Blood, in press.
Georgii-Hemming P, Wiklund HJ, Ljunggren ), Nilsson K (1996) Insulin-like growth factor I is a growth and survival factor in human multipe myeloma cell lines. Blood 88:2250–2258
Hallek M, Leif Bergsagel P, Anderson KC (1998) Multiple myeloma: increasing evidence for a multistep transformation process. Blood 91: 3 – 21
Harrington EA, Bennett MR, Fanidi A, Evan GI (1994) c-Myc-induced apoptosis in fibroblasts is inhibited by specific cytokines. EMBO J 13:3286–3295
Hata H, Matsuzaki H, Takeya M, Yoshida M, Sonoki T, Nagasaki A, Kuribayashi N, Kawano F, Takatsuki K (1995) Expression of Fas/Apo-1 (CD95) and apoptosis in tumor cells from patients with plasma cell disorders. Blood 86: 1939 - 1945
Idestrom K, Cantell K, Killander D, Nilsson K, Strander H, Willems J (1979) Interferon therapy in multiple myeloma. Acta Med Scand 205: 149 – 154
Jelinek DF, Witzig TE, Arendt BK (1997) A role for insulin-like growth factor in the regulation of IL-6-responsivehuman myeloma cell line growth. J Immunol 159: 487 – 496
Jernberg H, Pettersson M, Kishimoto T, Nilsson K (1991) Heterogeneity in response to interleukin 6 (IL-6), expression of IL-6 and IL-6 receptor mRNA in a panel of established human multiple myeloma cell lines. Leukemia 5: 255 – 265
Jernberg H, Zech L, Nilsson K (1987) Cytogenetic studies on human myeloma cell lines. Int J Cancer 40: 811 – 817
Jernberg-Wiklund H, Pettersson M, Carlsson M, Nilsson K (1992a) Increase in interleukin 6 (IL- 6) and IL-6 receptor expression in a human multiple myeloma cell line, U-266, during long- term in vitro culture and the development of a possible autocrine IL-6 loop. Leukemia 6: 310 – 318
Jernberg-Wiklund H, Pettersson M, Larsson LG, Anton R, Nilsson K (1992b) Expression of myc- family genes in established human multiple myeloma cell lines: L-myc but not c-myc gene expression in the U-266 myeloma cell line. Int J Cancer 51: 116 – 123
Jourdan M, Zhang XG, Portier M, Boiron JM, Bataille R, Klein B (1991) IFN-alpha induces autocrine production of IL-6 in myeloma cell lines. J Immunol 147: 4402 – 4407
Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K, Asaoku H, Tang B, Tanabe O, Tanaka H, Kuramota A, Kishimoto T (1988) Nature 332: 83 – 85
Klein B, Zhang XG, Jourdan M, Boiron JM, Portier M, Lu ZY, Wijdenes J, Brochier J, Bataille R (1990) Interleukin-6 is the central tumor growth factor in vitro and in vivo in multiple myeloma.Eur Cytokine Netw: 193–201
Klein B, Zhang XG, Jourdan M, Content J, Houssiau F, Aarden L, Piechaczyk M, Bataille R (1989) Paracrine rather than autocrine regulation of myeloma-cell growth anddifferentiation by interleukin-6. Blood 73: 517 – 526
Ludwig CU, Durie BG, Salmon SE, Moon TE (1983) Tumor growth stimulation in vitro by interferons. Eur J Cancer Clin Oncol 19: 1625 – 1632
Nagata S, Golstein P (1995) The Fas death factor. Science 267: 1449 – 1456
Nilsson K (1977) Established cell lines as tools in the study of human lymphoma and myeloma cell characteristics. Hamatol Bluttransfus 20: 253 – 264
Nilsson K (1992) Human B-lymphoid cell lines. Hum Cell 5: 25 – 41
Nilsson K (1994) The control of growth in human multiple myeloma cell lines. In Multiple Myeloma and related Disorders, B Barlogie, F Dammacco. Eds. ( Rome, Italy: Ares-Serono Symposia Publications ) pp 83 – 92
Nilsson K, Bennich H, Johansson SG, Ponten J (1970) Established immunoglobulin producing myeloma (IgE) and lymphoblastoid (IgG) cell lines from an IgE myeloma patient. Clin Exp Immunol 7: 477 – 489
Nilsson K, Jernberg H, Pettersson M (1990) IL-6 as a growth factor for human multiple myeloma cells—a short overview. Curr Top Microbiol Immunol 166: 3 – 12
Pettersson M, Jernberg-Wiklund H, Larsson LG, Sundstrom C, Givol I, Tsujimoto Y, Nilsson K ( 1992 Expression of the bcl-2 gene in human multiple myeloma cell lines and normalplasma cells. Blood 79: 495 – 502
Portier M, Zhang XG, Caron E, Lu ZY, Bataille R, Klein B (1993) gamma-Interferon in multiple myeloma: inhibition of interleukin-6 (IL-6)-dependent myeloma cell growth and downregulation of IL-6-receptor expression in vitro. Blood 81:3076–3082
Sati HI, Apperley JF, Greaves M, Lawry J, Gooding R, Russell RG, Croucher PI (1998) Interleukin-6 is expressed by plasma cells from patients with multiple myeloma and monoclonal gammopathy of undetermined significance. Br J Haematol 101: 287 – 295
Scibienski RJ, Paglieroni T, Caggiano V, Lemongello D, Gumerlock PH, Mackenzie MR (1992) Factors affecting the in vitro evolution of a myeloma cell line. Leukemia 6: 940 – 947
Selleri C, Sato T, Del Vecchio L, Luciano L, Barrett AJ, Rotoli B, Young NS, Maciejewski JP (1997) Involvement of Fas-mediated apoptosis in the inhibitory effects of interferon-alpha in chronic myelogenous leukemia. Blood 89: 957 – 964
Shima Y, Nishimoto N, Ogata A, Fujii Y, Yishisaki K, Kishimoto T (1995) Myeloma cells express Fas antigen/Apo-1 (CD95) but only some are sensistive to anti-Fas antibody resulting in apoptosis. Blood 85: 757 – 764
Spets H, Georgii-Hemming P, Siljason J, Nilsson K, Jernberg-Wiklund H (1998) Fas/APO-1 (CD95)-mediated apoptosis is activated by interferon-gamma and interferon- in interleukin-6 (IL-6)-dependent and IL-6-independent multiplemyeloma cell lines. Blood 92: 2914 – 2923
Spets H, Jernberg-Wiklund H, Sambade C, Soderberg O, Nilsson K (1997) The effects on growth and survival of IL-6 can be dissociated in theU-266-1970/U-266-1984 and HL407E/HL407L human multiple myeloma cell lines. Br J Haematol 98: 126 – 133
Van Riet I, De Greef C, Aharchi F, Woischwill C, De Waele M, Bakkus M, Lacor P, Schots R, Van Camp B (1997) Establishment and characterization of a human stroma-dependent myeloma cell line (MM5.1) and its stroma-independent variant (MM5.2). Leukemia 11: 284 – 293
Westendorf JJ, Ahmann GJ, Armitage RJ, Spriggs MK, Lust JA, Greipp PR, Katzmann JA, Jelinek DF(1994) CD40 expression in malignant plasma cells. Role in stimulation of autocrineIL-6 secretion by a human myeloma cell line. J Immunol 152:117–128
Westendorf JJ, Lammert JM, Jelinek DF (1995) Expression and function of Fas (APO-1/CD95) in patient myeloma cells and myeloma cell lines. Blood 85: 3566 – 3576
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Nilsson, K., Georgii-Hemming, P., Spets, H., Jernberg-Wiklund, H. (1999). The Control of Proliferation, Survival and Apoptosis in Human Multiple Myeloma Cells in vitro . In: Melchers, F., Potter, M. (eds) Mechanisms of B Cell Neoplasia 1998. Current Topics in Microbiology and Immunology, vol 246. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-60162-0_40
Download citation
DOI: https://doi.org/10.1007/978-3-642-60162-0_40
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-64283-8
Online ISBN: 978-3-642-60162-0
eBook Packages: Springer Book Archive